Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cowen & Co. Maintains Outperform on Varonis Systems, Lowers Price Target to $35

Cowen & Co. analyst Shaul Eyal maintains Varonis Systems (NASDAQ:VRNS) with a Outperform and lowers the price target from $53 to $35.
byBenzinga Newsdesk
November 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Cowen & Co. analyst Shaul Eyal maintains Varonis Systems (NASDAQ:VRNS) with a Outperform and lowers the price target from $53 to $35.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain

By Jelena Martinovic
April 23, 10:24 AM
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA, for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the company initiated the regulatory process with the FDA for the approval of its prolonged CBD release technology for human use.

CSE:INNO